

ANNOUNCEMENT

GRIFOLS, S.A. (“GRIFOLS”) and TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. (“TALECRIS”) announce that, on May 31, 2011, the US Federal Trade Commission (“FTC”) accepted for public comment a Consent Agreement with GRIFOLS and TALECRIS by means of which the conditions for the merger transaction between both companies are agreed.

The Consent Agreement requires that, within ten (10) days after Grifols acquires Talecris, Grifols must divest to the Italian company KEDRION S.P.A., in accordance with the Consent Agreement

- the Melville, New York fractionation facility;
- two plasma collection centers located in Mobile, Alabama, and Winston Salem, North Carolina;
- an agreed quantity of plasma; and
- the exclusive right to sell in the United States the Factor VIII product sold under TALECRIS’ brand name Koate.

In addition, the Consent Agreement requires GRIFOLS to enter into various agreements with KEDRION to implement the Consent Agreement (collectively, the “Divestiture Agreement”), including

- a 300,000 liters of plasma contract manufacturing agreement under which GRIFOLS will for seven (7) years manufacture for sale by KEDRION in the United States Koate, private label IVIG and private label albumin; and
- a five (5)-year option for KEDRION to purchase a non-exclusive license to Koate intellectual property for use in Koate in United States.

The Consent Agreement permits GRIFOLS to lease the Melville facility from KEDRION for up to four years pursuant to the Divestiture Agreement.

The Consent Agreement includes appointment of an independent Monitor to oversee GRIFOLS’ compliance with the Consent Agreement and requires GRIFOLS to submit reports periodically to the Commission setting forth in detail the manner and form in which Grifols intends to comply, is complying, and has complied with the Consent Agreement.

As a result of this approval, the operations related to the acquisition of Talecris will start as of today in Spain and in United States.

GRIFOLS states that neither the Consent Agreement nor Divestiture Agreement signed with KEDRION will affect the operating synergies that GRIFOLS expects to achieve at the combined company with the merger transaction.

In Barcelona, on June 1, 2011

Raimon Grifols Roura
Secretary of the Board of Directors

